Drug intelligence / Profile preview

capmatinib + larotrectinib

Development stage: Preclinical
Lead developer: Incyte
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of capmatinib, a MET inhibitor, and larotrectinib, a TRK inhibitor. Capmatinib targets MET exon 14 skipping mutations and MET amplification, while larotrectinib targets NTRK gene fusions. Both drugs have demonstrated CNS penetration and activity against brain metastases. This combination might be considered in cases where both MET alterations and NTRK fusions are present, though clinical evidence for this specific combination is limited.

Targets

NTRK3 (Tropomyosin receptor kinase C)NTRK1 (Tropomyosin-related receptor kinase A)NTRK2 (Tropomyosin-related kinase receptor type B)MET (Mesenchymal-epithelial transition factor receptor)

Beyond the preview

Go deeper on capmatinib + larotrectinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on capmatinib + larotrectinib.

Explore the full profile